NEW YORK, June 01, 2022 (GLOBE NEWSWIRE) -- Intrommune Therapeutics, Inc., a New York-based, clinical stage biotechnology company developing a patient-friendly treatment platform for peanut and other ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback